Medivation Inc.


Medivation Inc (MDVN)’s Price Targets To Increase Based On Xtandi’s Impressive Breast Cancer Efficacy

  I generally advise investors which small cap biotech stocks are worth a look. Medivation Inc (NASDAQ:MDVN) was a small cap stock when …

Maxim Group Raises Price Target for Medivation Inc Following ASCO Data Review and Meeting with CMO

Maxim Group analyst Jason Kolbert came out with a favorable report on Medivation Inc (NASDAQ:MDVN), raising the price target to $168 (from $155), …

Stock Update (NASDAQ:MDVN): Medivation Inc New Enzalutamide Data in Triple-Negative Breast Cancer Presented at the 2015 ASCO Annual Meeting

Medivation Inc (NASDAQ:MDVN) announced that data from a Phase 2 study evaluating the investigational use of enzalutamide as a single agent for the treatment …

Company Update (NASDAQ:MDVN): Medivation Inc Names Andrew Powell General Counsel

Medivation Inc (NASDAQ:MDVN) announced the appointment of Andrew Powell as senior vice president, general counsel and corporate secretary, effective May 27, 2015. Andrew …

Stock Update (NASDAQ:MDVN): Medivation Inc Reports First Quarter 2015 Financial Results

Medivation Inc (NASDAQ:MDVN) reported its financial results for the first quarter endedMarch 31, 2015. U.

More Details Emerge on Medivation’s XTANDI in Prostate Cancer

Medivation Inc (NASDAQ:MDVN) issued a joint statement with Astellas Pharma on Monday announcing detailed results for the use of enzalutamide in castration-resistant prostate …

Brean Capital Boosts Price Target For Medivation Following 4Q14 Results

In a research report published Thursday, Brean Capital analyst Jonathan Aschoff reiterated a Buy rating on Medivation Inc (NASDAQ:MDVN) and raised the price target to $125 (from $118), …

Medivation Remains One Of Our Top Ideas For 2014, Says Janney

In a research report issued today, Janney Capital analyst Kimberly Lee maintained a Buy rating on Medivation Inc. (MDVN) with a $110 price target, which …

Stay Ahead of Everyone Else

Get The Latest Stock News Alerts